In the 2018 Alzheimer’s Association International Conference (AAIC), a research framework for AD including 3 biomarker groupings was presented: aggregated Aβ (A), aggregated tau (T), and neurodegeneration or neuronal injury (N) [2]. The gene discussed is MAPT; the disease is Alzheimer disease.